Healthequity (NASDAQ:HQY) had its price target increased by Wells Fargo & Co from $84.00 to $105.00 in a report issued on Wednesday, The Fly reports. The firm currently has an outperform rating on the stock.
A number of other equities research analysts have also issued reports on HQY. KeyCorp increased their target price on Healthequity from $90.00 to $105.00 and gave the company an overweight rating in a research note on Tuesday. Cantor Fitzgerald lowered Healthequity from an overweight rating to a neutral rating and set a $65.00 target price for the company. in a research note on Wednesday, May 30th. Robert W. Baird increased their target price on Healthequity from $61.00 to $77.00 and gave the company a neutral rating in a research note on Tuesday, June 5th. Bank of America assumed coverage on Healthequity in a research note on Wednesday, May 23rd. They issued a buy rating and a $83.00 target price for the company. Finally, Barrington Research increased their target price on Healthequity to $85.00 and gave the company an outperform rating in a research note on Tuesday, June 5th. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. Healthequity has a consensus rating of Buy and a consensus target price of $92.08.
Shares of NASDAQ:HQY opened at $97.07 on Wednesday. The stock has a market cap of $5.92 billion, a price-to-earnings ratio of 179.76, a PEG ratio of 2.55 and a beta of 1.47. Healthequity has a 12 month low of $42.92 and a 12 month high of $97.93.
Healthequity (NASDAQ:HQY) last announced its quarterly earnings results on Tuesday, September 4th. The company reported $0.34 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.12. The company had revenue of $71.10 million during the quarter, compared to analyst estimates of $69.84 million. Healthequity had a return on equity of 12.58% and a net margin of 23.81%. The firm’s revenue was up 25.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.27 earnings per share. sell-side analysts anticipate that Healthequity will post 1.13 EPS for the current fiscal year.
In other Healthequity news, Director Frank Medici sold 15,596 shares of the firm’s stock in a transaction that occurred on Tuesday, July 10th. The stock was sold at an average price of $80.15, for a total transaction of $1,250,019.40. Following the completion of the sale, the director now owns 26,341 shares in the company, valued at approximately $2,111,231.15. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Darcy G. Mott sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, August 20th. The shares were sold at an average price of $86.37, for a total value of $345,480.00. Following the sale, the vice president now owns 99,200 shares of the company’s stock, valued at approximately $8,567,904. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,500 shares of company stock valued at $3,312,481. 4.00% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in HQY. Citigroup Inc. lifted its holdings in Healthequity by 414.4% during the 1st quarter. Citigroup Inc. now owns 2,639 shares of the company’s stock worth $160,000 after buying an additional 2,126 shares during the last quarter. Advisors Asset Management Inc. lifted its holdings in Healthequity by 5,212.2% during the 2nd quarter. Advisors Asset Management Inc. now owns 72,086 shares of the company’s stock worth $160,000 after buying an additional 70,729 shares during the last quarter. Rockefeller Capital Management L.P. bought a new position in Healthequity during the 2nd quarter worth approximately $179,000. Cim LLC bought a new stake in shares of Healthequity in the 2nd quarter worth approximately $204,000. Finally, S&CO Inc. bought a new stake in shares of Healthequity in the 2nd quarter worth approximately $204,000. 97.12% of the stock is currently owned by institutional investors.
Healthequity Company Profile
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Further Reading: What is a Tariff?
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.